

**CANCER CARE OF WNC PROTOCOL STATUS**

**Actively enrolling treatment trials!**

**NON SMALL CELL LUNG:**

**NovaRx NR001-03** - Phase III Study of Lucanix™ **Vaccine** in Advanced Non-small Cell Lung Cancer: Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy.

**Boehringer Ingelheim:** Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer **after failure of first line chemotherapy. ALIMTA Provided**

**SCRI: LUN 142:** A Randomized Phase II Trial of **Adjuvant** Carboplatin and Docetaxel +/- Bevacizumab and TARCEVA in Patients with Resected Non-Small Cell Lung Cancer Stage IB – IIIA, (resected squamous eligible) (**Bevacizumab and Tarceva provided**)

**COLORECTAL:**

**UNC Lineberger Comprehensive Cancer Center 0918:** Multicenter Study Investigating Utilization of Pharmacokinetic-Guide 5-Fluorouracil in Patients Receiving **MFOLFOX6** With or Without Bevacizumab

**AMGEN 20080259** --- A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Administered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With **Bevacizumab** and Either (FOLFOX) or (FOLFIRI)

**Epigenomics, Inc.** SPR 0019P: Sample Collection Protocol - Colorectal Cancer (CRC) Recurrence Monitoring

**NON-HODGKIN'S LYMPHOMA:**

**Novartis: A phase III study of RAD001** (Everolimus) adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo **after patients have achieved complete response with first-line rituximab-CHOP.**

**PANCREATIC:**

**Threshold TH-CR-404:** A randomized Cross-Over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination with Gemcitabine Compared with Gemcitabine Alone in Previously Untreated Patients with Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma